NASDAQ: MNPR Monopar Therapeutics 10-K

Monopar delays ALXN1840 NDA to mid-2026 amid FDA dialogue; raises $92M, extends runway to 2027

Filed March 27, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 31, 2025 · ~1 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade MNPR commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.